Interestingly, LSD1 inhibitors sensitize both AML and APL blasts to physiological concentrations of retinoic acid [329] and induce differentiation in AML cells by displacing the LSD1-coREST complex from the GFI1 enhancer, suggesting a wide potential of these drugs [330]. Here, KDM1A is linked to acute promyelocytic leukemia.